Analyst Ratings for Crescent Biopharma Inc (CBIO)
CBIO Rating Summary
CBIO Price Target Summary
- Highest: $35.00 (Guggenheim)
- Lowest: $22.00 (LifeSci Capital)
- Average: $28.00
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$28.00 (+55.7%)
* Over Last 12-Mos
Rating Score: 6.9 / 10
Percentile Rank: 74%
Avg. $ Target:
$28.00 (+55.7%)
* Over Last 12-Mos
Rating Score: 6.9 / 10
Percentile Rank: 74%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/1/2026 | H.C. Wainwright | Mitchell S. Kapoor | Downgrade | Neutral (Buy) |
N/A (N/A) |
20.65 (17.98) |
-12.93% | Details |
| 1/28/2026 | Piper Sandler | Biren Amin | New Coverage | Overweight (N/A) |
N/A (N/A) |
11.75 (17.98) |
53.02% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
